19.59
price down icon2.49%   -0.50
after-market Dopo l'orario di chiusura: 19.52 -0.07 -0.36%
loading
Precedente Chiudi:
$20.09
Aprire:
$20.12
Volume 24 ore:
2.93M
Relative Volume:
1.23
Capitalizzazione di mercato:
$2.46B
Reddito:
$715.22M
Utile/perdita netta:
$-250.10M
Rapporto P/E:
-9.6502
EPS:
-2.03
Flusso di cassa netto:
$-205.58M
1 W Prestazione:
+0.62%
1M Prestazione:
+6.53%
6M Prestazione:
-34.70%
1 anno Prestazione:
-49.61%
Intervallo 1D:
Value
$19.33
$20.30
Intervallo di 1 settimana:
Value
$19.09
$20.32
Portata 52W:
Value
$16.10
$41.94

Apellis Pharmaceuticals Inc Stock (APLS) Company Profile

Name
Nome
Apellis Pharmaceuticals Inc
Name
Telefono
617-977-5700
Name
Indirizzo
100 FIFTH AVENUE, WALTHAM, KY
Name
Dipendente
710
Name
Cinguettio
@ApellisPharma
Name
Prossima data di guadagno
2024-12-05
Name
Ultimi documenti SEC
Name
APLS's Discussions on Twitter

Confronta APLS con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
APLS
Apellis Pharmaceuticals Inc
19.59 2.52B 715.22M -250.10M -205.58M -2.03
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.65 122.48B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.10 60.96B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.81 42.77B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.99 36.21B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.47 31.91B 3.81B -644.79M -669.77M -6.24

Apellis Pharmaceuticals Inc Stock (APLS) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-05-09 Downgrade BofA Securities Buy → Neutral
2025-05-09 Downgrade Raymond James Strong Buy → Outperform
2025-04-29 Iniziato Cantor Fitzgerald Overweight
2024-12-17 Downgrade Goldman Buy → Neutral
2024-11-21 Iniziato Morgan Stanley Equal-Weight
2024-10-25 Iniziato RBC Capital Mkts Sector Perform
2024-10-16 Iniziato Scotiabank Sector Outperform
2024-10-16 Iniziato William Blair Outperform
2024-05-31 Iniziato Piper Sandler Neutral
2024-02-05 Aggiornamento Jefferies Hold → Buy
2023-12-14 Downgrade Wells Fargo Overweight → Equal Weight
2023-11-09 Iniziato Goldman Buy
2023-11-02 Iniziato Mizuho Neutral
2023-10-06 Aggiornamento JP Morgan Neutral → Overweight
2023-09-15 Aggiornamento Wells Fargo Equal Weight → Overweight
2023-08-29 Reiterato Citigroup Buy
2023-08-03 Downgrade JP Morgan Overweight → Neutral
2023-08-01 Downgrade BofA Securities Buy → Neutral
2023-01-03 Downgrade Wells Fargo Overweight → Equal Weight
2022-11-10 Downgrade Jefferies Buy → Hold
2022-07-19 Iniziato H.C. Wainwright Buy
2022-06-17 Ripresa Stifel Buy
2022-04-14 Downgrade ROTH Capital Neutral → Sell
2021-12-08 Iniziato Wells Fargo Overweight
2021-11-29 Downgrade ROTH Capital Buy → Neutral
2021-09-10 Reiterato BMO Capital Markets Outperform
2021-09-10 Reiterato Credit Suisse Neutral
2021-09-10 Reiterato Needham Buy
2021-09-10 Reiterato Oppenheimer Outperform
2021-09-10 Downgrade Wedbush Outperform → Neutral
2021-08-19 Iniziato Jefferies Buy
2021-08-19 Aggiornamento Wedbush Neutral → Outperform
2021-05-21 Iniziato UBS Buy
2021-04-16 Iniziato Goldman Buy
2020-11-19 Iniziato Needham Buy
2020-09-01 Iniziato Stifel Buy
2020-07-20 Iniziato ROTH Capital Buy
2020-06-17 Iniziato BTIG Research Neutral
2020-04-01 Iniziato Raymond James Strong Buy
2020-03-31 Iniziato BMO Capital Markets Outperform
2020-03-11 Aggiornamento Wedbush Underperform → Neutral
2020-01-07 Iniziato SVB Leerink Mkt Perform
2019-12-19 Iniziato BofA/Merrill Buy
2019-11-22 Iniziato Wedbush Underperform
2019-11-05 Iniziato Credit Suisse Neutral
2019-08-01 Reiterato Cantor Fitzgerald Overweight
2019-07-12 Aggiornamento JP Morgan Neutral → Overweight
2019-03-29 Iniziato Robert W. Baird Outperform
2019-01-23 Downgrade JP Morgan Overweight → Neutral
2018-07-30 Aggiornamento B. Riley FBR Neutral → Buy
2018-05-24 Iniziato Cantor Fitzgerald Overweight
2018-04-12 Downgrade B. Riley FBR, Inc. Buy → Neutral
2018-02-08 Iniziato B. Riley FBR, Inc. Buy
Mostra tutto

Apellis Pharmaceuticals Inc Borsa (APLS) Ultime notizie

pulisher
06:24 AM

What analysts say about Apellis Pharmaceuticals Inc. stockSky-high return potential - Autocar Professional

06:24 AM
pulisher
Jul 24, 2025

Apellis Pharmaceuticals to Host Conference Call on July 31, 2025 - GuruFocus

Jul 24, 2025
pulisher
Jul 24, 2025

Apellis Pharmaceuticals to Host Conference Call on July 31, 2025, to Discuss Second Quarter 2025 Financial Results - The Manila Times

Jul 24, 2025
pulisher
Jul 23, 2025

Is Apellis Pharmaceuticals Inc. a good long term investmentDynamic investment growth - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 23, 2025

Complement 3 Glomerulopathy Market Expected to Experience Major Growth by 2034, According to DelveInsight | NovelMed Therapeutics, Apellis Pharma, Novartis, Amyndas Pharma - Barchart.com

Jul 23, 2025
pulisher
Jul 23, 2025

Apellis Pharmaceuticals Inc. Stock Analysis and ForecastOutstanding trading profits - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 22, 2025

What drives Apellis Pharmaceuticals Inc. stock priceExceptional market performance - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 21, 2025

Intermediate Age-Related Macular Degeneration Market Research 2025-2035 Featuring Novartis, Allegro Ophthalmics, and Apellis PharmaceuticalsResearchAndMarkets.com - FinancialContent

Jul 21, 2025
pulisher
Jul 18, 2025

Baird Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Raises Target Price to $50 - 富途牛牛

Jul 18, 2025
pulisher
Jul 18, 2025

Apellis Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (15 Ratings) - Benzinga

Jul 18, 2025
pulisher
Jul 18, 2025

Fierce Biotech Layoff Tracker 2025: Sail shrinks crew again; Sarepta lays off 500 staffers - Fierce Biotech

Jul 18, 2025
pulisher
Jul 16, 2025

APLS Stock Update: B of A Securities Raises Price Target | APLS - GuruFocus

Jul 16, 2025
pulisher
Jul 15, 2025

Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting - The Manila Times

Jul 15, 2025
pulisher
Jul 15, 2025

Apellis Reveals 48-Month SYFOVRE Data: 5 Key Studies Show Promise for Geographic Atrophy Treatment - Stock Titan

Jul 15, 2025
pulisher
Jul 14, 2025

H.C. Wainwright reiterates Buy rating on Apellis Pharmaceuticals stock By Investing.com - Investing.com Canada

Jul 14, 2025
pulisher
Jul 14, 2025

How the (APLS) price action is used to our Advantage - news.stocktradersdaily.com

Jul 14, 2025
pulisher
Jul 11, 2025

Apellis Pharmaceuticals (APLS) Receives a Buy from Cantor Fitzgerald - The Globe and Mail

Jul 11, 2025
pulisher
Jul 11, 2025

Apellis stock holds Outperform rating at William Blair amid Izervay competition - Investing.com Canada

Jul 11, 2025
pulisher
Jul 10, 2025

Apellis Sells Aspaveli Ex-US Royalties to Sobi for Up to $300M - MSN

Jul 10, 2025
pulisher
Jul 10, 2025

Cantor Fitzgerald reiterates Apellis stock Overweight rating with $39 target By Investing.com - Investing.com Canada

Jul 10, 2025
pulisher
Jul 10, 2025

Analysts Offer Insights on Healthcare Companies: Apellis Pharmaceuticals (APLS) and Charles River Labs (CRL) - The Globe and Mail

Jul 10, 2025
pulisher
Jul 08, 2025

16 Most Promising Stocks According to Wall Street Analysts - Insider Monkey

Jul 08, 2025
pulisher
Jul 07, 2025

Morgan Stanley Raises PT on Apellis Pharmaceuticals (APLS) to $26, Keeps a Hold Rating - MSN

Jul 07, 2025
pulisher
Jul 07, 2025

Morgan Stanley raised the Target Price of Apellis Pharmaceuticals (APLS.US) to $26 and maintained a "Hold" rating. - 富途牛牛

Jul 07, 2025
pulisher
Jul 06, 2025

Apellis stock surges after Sobi $300 million royalty deal - MSN

Jul 06, 2025
pulisher
Jul 05, 2025

Apellis Pharmaceuticals, Inc. (APLS) Insider Activity Signals Possible Market Mispricing - MSN

Jul 05, 2025
pulisher
Jul 03, 2025

SHAREHOLDER ALERT: Potential Recovery for Apellis Pharmaceuticals, Inc. (APLS) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire

Jul 03, 2025
pulisher
Jul 03, 2025

WilmerHale Advises Apellis Pharmaceuticals in Purchase Agreement with Sobi - WilmerHale

Jul 03, 2025
pulisher
Jul 03, 2025

(APLS) Trading Advice - news.stocktradersdaily.com

Jul 03, 2025
pulisher
Jul 03, 2025

Apellis signs royalty purchase deal with Sobi for Aspaveli - MSN

Jul 03, 2025
pulisher
Jul 03, 2025

Apellis Stock Rises on $300M Royalty Deal With Sobi for Aspaveli - MSN

Jul 03, 2025
pulisher
Jul 03, 2025

Analysts Offer Insights on Healthcare Companies: BeiGene (ONC), Apellis Pharmaceuticals (APLS) and Pliant Therapeutics (PLRX) - The Globe and Mail

Jul 03, 2025
pulisher
Jul 02, 2025

What 13 Analyst Ratings Have To Say About Apellis Pharmaceuticals - Nasdaq

Jul 02, 2025
pulisher
Jul 02, 2025

Mizuho maintains Neutral rating on Apellis stock amid royalty deal with Sobi - Investing.com Canada

Jul 02, 2025

Apellis Pharmaceuticals Inc Azioni (APLS) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Apellis Pharmaceuticals Inc Azioni (APLS) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Francois Cedric
Chief Executive Officer
Jul 17 '25
Sale
20.21
19,725
398,735
331,605
Watson David O.
General Counsel
Jul 16 '25
Sale
19.55
5,000
97,750
128,730
$23.40
price down icon 0.97%
$36.67
price up icon 0.22%
$103.95
price up icon 0.42%
$28.67
price up icon 3.99%
$115.31
price up icon 0.65%
biotechnology ONC
$291.47
price down icon 1.68%
Capitalizzazione:     |  Volume (24 ore):